Barocas Joshua A, Erdman Elizabeth A, Westfall Matthew Y, Christine Paul J, Bernson Dana, Villani Jennifer, Doogan Nathan J, White Laura, Walley Alexander Y, Bettano Amy, Wang Jianing
Division of General Internal Medicine, University of Colorado School of Medicine, Aurora, CO, USA.
Division of Infectious Diseases, University of Colorado School of Medicine, Aurora, CO, USA.
Addiction. 2025 Apr;120(4):711-720. doi: 10.1111/add.16726. Epub 2024 Dec 16.
Stimulant-involved overdose deaths are increasing throughout the United States. Because stimulant misuse (i.e. taking a prescribed medicine not as directed) and stimulant use disorder contribute to the surging number of stimulant-related deaths, knowing the prevalence of stimulant misuse and use disorder is important. We aimed to estimate the prevalence of stimulant misuse and/or use disorder in Massachusetts from 2014 to 2021.
DESIGN, SETTING AND PARTICIPANTS: This was a cohort study using a multiple systems estimation approach (previously known as 'capture-recapture'), using multiple individually linked epidemiological data sources, located in the Commonwealth of Massachusetts, 2014-2021. People aged 18-64 years from administrative databases were linked at the individual level and included in the analysis.
Measurements included known and estimated counts of people with stimulant misuse and/or use disorder (as defined in each individual database) as well as total count and prevalence in Massachusetts. We performed both a stratified analysis using log-linear models to estimate the unknown population with stimulant misuse/use disorder and a single model analysis in which demographics were used as covariates. Uncertainty is characterized using 95% confidence intervals (95% CI) on the total counts and prevalence estimates.
The number of known individuals increased during the study period from 31 037 in 2014 to 42 612 in 2021. Using the multiple systems estimation approach, the estimated prevalence of underlying stimulant misuse and/or use disorder population ranged from 4.1 to 7.1% during the study period in the stratified analysis and 4.2 to 6.8% in the single model. By race, the highest prevalence estimates were among the Black non-Hispanic population, which showed a prevalence of up to 14.5% (95% CI = 14.32%, 14.57%) in 2021.
The estimated prevalence of stimulant misuse and/or use disorder in Massachusetts from 2014 to 2021 ranged from 4% to nearly 7% of the population. People from racial minorities appear to be disproportionately affected compared with the white non-Hispanic population. The unknown population accounted for large proportions of the total estimated population.
在美国,涉及兴奋剂的过量用药死亡人数正在增加。由于兴奋剂滥用(即未按医嘱服用处方药)和兴奋剂使用障碍导致与兴奋剂相关的死亡人数激增,了解兴奋剂滥用和使用障碍的患病率很重要。我们旨在估计2014年至2021年马萨诸塞州兴奋剂滥用和/或使用障碍的患病率。
设计、背景与参与者:这是一项队列研究,采用多系统估计方法(以前称为“捕获-再捕获”),使用多个单独关联的流行病学数据源,数据来自2014 - 2021年的马萨诸塞州。将行政数据库中18 - 64岁的人群在个体层面进行关联,并纳入分析。
测量包括已知和估计的兴奋剂滥用和/或使用障碍患者数量(如在每个单独数据库中所定义)以及马萨诸塞州的总数和患病率。我们使用对数线性模型进行分层分析以估计未知的兴奋剂滥用/使用障碍人群,还进行了单模型分析,其中将人口统计学特征用作协变量。使用总数和患病率估计值的95%置信区间(95%CI)来表征不确定性。
在研究期间,已知个体数量从2014年的31037人增加到2021年的42612人。在分层分析中,使用多系统估计方法,研究期间潜在兴奋剂滥用和/或使用障碍人群的估计患病率在4.1%至7.1%之间,在单模型中为4.2%至6.8%。按种族划分,患病率估计最高的是非西班牙裔黑人人群,2021年其患病率高达14.5%(95%CI = 14.32%,14.57%)。
2014年至2021年,马萨诸塞州兴奋剂滥用和/或使用障碍的估计患病率在该州人口的4%至近7%之间。与非西班牙裔白人人群相比,少数族裔人群受影响的比例似乎过高。未知人群在估计总人口中占很大比例。